Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals

被引:26
作者
Tamaki, Nobuharu [1 ,2 ]
Higuchi, Mayu [1 ]
Kurosaki, Masayuki [1 ]
Kirino, Sakura [1 ]
Osawa, Leona [1 ]
Watakabe, Keiya [1 ]
Wang, Wan [1 ]
Okada, Mao [1 ]
Shimizu, Takao [1 ]
Takaura, Kenta [1 ]
Takada, Hitomi [1 ,2 ]
Kaneko, Shun [1 ]
Yasui, Yutaka [1 ]
Tsuchiya, Kaoru [1 ]
Nakanishi, Hiroyuki [1 ]
Itakura, Jun [1 ]
Takahashi, Yuka [1 ]
Enomoto, Nobuyuki [2 ]
Izumi, Namiki [1 ]
机构
[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan
[2] Univ Yamanashi, Fac Med, Dept Internal Med 1, Chuo Ku, Kofu, Yamanashi, Japan
关键词
chronic hepatitis C; FIB-4; hepatocellular carcinoma; magnetic resonance elastography; Wisteria floribunda agglutinin-positive mac-2 binding protein; MR ELASTOGRAPHY; LIVER FIBROSIS; LI-RADS; THERAPY; PREDICTOR; DIAGNOSIS; IMPACT;
D O I
10.1111/jvh.13103
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important, and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct-acting antivirals were included. Magnetic resonance elastography (MRE) and serum fibrosis markers were measured 12 weeks after the end of treatment, and the subsequent HCC development was examined. The mean observation period was 26.4 +/- 7.9 months, and 24 patients developed HCC. Area under the receiver operating characteristic curve of liver stiffness by MRE, Wisteria floribunda agglutinin-positive mac-2 binding protein and FIB-4 for predicting HCC within 3 years was 0.743, 0.697 and 0.647, respectively. The 1/2/3-year rates of HCC development in patients with liver stiffness >= 3.75 KPa were 6.6%, 11.9% and 14.5%, whereas they were 1.4%, 2.5% and 2.5% in patients with liver stiffness KPa (P < 0.001). Multivariate analysis revealed that liver stiffness >= 3.75 was an independent predictive factor for HCC development (hazard ratio, 3.51; 95% confidence interval, 1.24-9.99). In subgroup analysis, there were 132 patients who were KPa, and no HCC development was observed in these patients. Diagnostic accuracy for predicting HCC development was higher in MRE than serum fibrosis markers and measurement of liver stiffness by MRE could identify patients with high and low risk of HCC development after SVR.
引用
收藏
页码:893 / 899
页数:7
相关论文
共 30 条
  • [1] Akahane T, 2018, HEPATOL RES, V1, P13246
  • [2] α-Fetoprotein Levels After Interferon Therapy and Risk of Hepatocarcinogenesis in Chronic Hepatitis C
    Asahina, Yasuhiro
    Tsuchiya, Kaoru
    Nishimura, Takashi
    Muraoka, Masaru
    Suzuki, Yuichiro
    Tamaki, Nobuharu
    Yasui, Yutaka
    Hosokawa, Takanori
    Ueda, Ken
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Kurosaki, Masayuki
    Enomoto, Nobuyuki
    Nakagawa, Mina
    Kakinuma, Sei
    Watanabe, Mamoru
    Izumi, Namiki
    [J]. HEPATOLOGY, 2013, 58 (04) : 1253 - 1262
  • [3] 2017 Version of LI-RADS for CT and MR Imaging: An Update
    Elsayes, Khaled M.
    Hooker, Jonathan C.
    Agrons, Michelle M.
    Kielar, Ania Z.
    Tang, An
    Fowler, Kathryn J.
    Chernyak, Victoria
    Bashir, Mustafa R.
    Kono, Yuko
    Do, Richard K.
    Mitchell, Donald G.
    Kamaya, Aya
    Hecht, Elizabeth M.
    Sirlin, Claude B.
    [J]. RADIOGRAPHICS, 2017, 37 (07) : 1994 - 2017
  • [4] Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis
    Fujii, Hideki
    Kimura, Hiroyuki
    Kurosaki, Masayuki
    Hasebe, Chitomi
    Akahane, Takehiro
    Yagisawa, Hitoshi
    Kato, Keizo
    Yoshida, Hideo
    Itakura, Jun
    Sakita, Shinya
    Satou, Takashi
    Okada, Kazuhiko
    Kusakabe, Atsunori
    Kojima, Yuji
    Kondo, Masahiko
    Morita, Atsuhiro
    Nasu, Akihiro
    Tamada, Takashi
    Okushin, Hiroaki
    Kobashi, Haruhiko
    Tsuji, Keiji
    Joko, Kouji
    Ogawa, Chikara
    Uchida, Yasushi
    Mitsuda, Akeri
    Sohda, Tetsuro
    Ide, Yasushi
    Izumi, Namiki
    [J]. HEPATOLOGY RESEARCH, 2018, 48 (09) : 746 - 756
  • [5] Hanafy AS, 2018, HEPATOL RES, V20, P13303
  • [6] Higuchi M, 2018, CLIN GASTROENTEROL H, V28, P31323
  • [7] Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy
    Iio, Etsuko
    Shimada, Noritomo
    Takaguchi, Koichi
    Senoh, Tomonori
    Eguchi, Yuichiro
    Atsukawa, Masanori
    Tsubota, Akihito
    Abe, Hiroshi
    Kato, Keizo
    Kusakabe, Atsunori
    Miyaki, Tomokatsu
    Matsuura, Kentaro
    Matsunami, Kayoko
    Shinkai, Noboru
    Fujiwara, Kei
    Nojiri, Shunsuke
    Tanaka, Yasuhito
    [J]. HEPATOLOGY RESEARCH, 2017, 47 (12) : 1308 - 1316
  • [8] Itokawa N, 2018, HEPATOL RES, V11, P13256
  • [9] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    Kanda, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
  • [10] Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
    Kanwal, Fasiha
    Kramer, Jennifer
    Asch, Steven M.
    Chayanupatkul, Maneerat
    Cao, Yumei
    El-Serag, Hashem B.
    [J]. GASTROENTEROLOGY, 2017, 153 (04) : 996 - +